Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer

Lohrisch, Caroline A.; Paltiel, Chuck; Gelmon, Karen A.; Speers, Caroline; Taylor, S. G.; Barnett, Jeff; Olivotto, Ivo A.

doi:10.1200/jco.2005.01.6089

Cited by 326 publications

(217 citation statements)

References 28 publications

Supporting

Mentioning

206

Contrasting

Unclassified

Order By: Relevance

“…The use of 'random start cycles' avoids this requirement and minimise the delays in initiating fertility preservation treatment [28] and ultimately ensures the prompt onset of essential cancer therapy. There is evidence to suggest that cancer survival rates were only reduced when the time from surgery to chemotherapy exceeded 12 weeks [20]. In our study, the longest time from being seen in the unit to oocyte retrieval was 47 days, which therefore is far less than the 12 weeks limit quoted in the Lohrisch study.…”

Section: Discussioncontrasting

confidence: 57%

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Barcroft

Dayoub

Thong

2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose Determine the outcome of embryo cryopreservation in female oncology patients Methods The outcomes of IVF/ICSI cycles in oncology patients over 15 years in a University Teaching Hospital. Results Forty-two oncology patients (mean 31.9±3.9 years) underwent embryo cryopreservation treatment (n=33 IVF, n=6 ICSI). Controlled ovarian stimulation with GnRH antagonist protocol (n=34; 81 %) yielded fewer oocytes than GnRH agonist protocol (n=8; 19 %) (9.4±6.3 vs. 15.3±8.9; p=0.04) respectively. There was no significant difference in mean (±SD) duration of ovarian stimulation (11.6±2.6 vs.10.6±2.7), median gonadotrophin dose (1950( vs. 1670, median day 5-6 oestradiol level (1124 vs.1129 pmol/l) or embryo yield (6.2±4.1 vs. 8.8± 4.3; p=0.07) between GnRH antagonist and agonist treatment cycles respectively. Thirty-nine patients cryopreserved embryos and three had their cycle cancelled. During this study period, of those who cryopreserved embryos, 5 patients underwent 9 frozen-thaw cycles (13 %), resulting in 2 live births (1 twin, 1 singleton, live birth rate 22 %). Six patients died (15 %), 3 conceived naturally (8 %) and 2 couples separated (5 %). Fourteen patients discarded their embryos (36 %). Twenty-two patients' (56 %) have embryos remaining in storage. Conclusions This study demonstrates that embryo cryopreservation in female oncology patients gives a satisfactory live birth rate. However, there are concerns regarding costeffectiveness, resulting from high disposal/non-usage of embryos, and further studies are required.

show abstract

Section: Discussioncontrasting

confidence: 57%

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Barcroft

Dayoub

Thong

2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…In contrast, it is accepted that delays to adjuvant therapy can reduce survival 25,26 . Some recent studies have shown benefits for decreased wait times to surgery 1,2 , but other studies have contradicted those results 3 .…”

Section: Discussionmentioning

confidence: 99%

Coordination of Radiologic and Clinical Care Reduces the Wait Time to Breast Cancer Diagnosis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…With the exception of patients necessitating neo-adjuvant therapy for whom chemotherapy is initiated within 2-3 weeks, a window of 6-8 weeks commonly exists between surgery and the start of chemotherapy. Supposedly, in an early-staged disease, this interval of time can be extended to up to 12 weeks without compromising prognosis [66,67]. This allows a reasonable period to complete an IVF cycle, assuming that early referral is carried out.…”

Section: Timing and Schedule Flexibilitymentioning

confidence: 99%

IVF for fertility preservation in breast cancer patients—efficacy and safety issues

Shapira

Raanani

Meirow

2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Background Potential risks on future fertility have become a dominant issue in consultation and management of newly diagnosed young cancer patients. Several fertility preservation strategies are currently available. Of those, ovarian stimulation followed by IVF and embryo cryopreservation is the most established one and is especially applicable in reproductive aged breast cancer patients. Aim The aim of this study is to provide a comprehensive review on ovarian stimulation and IVF for fertility preservation in newly diagnosed breast cancer patients. Methods Review of relevant literature is available through PubMed and Google scholar. Results The use of IVF for fertility preservation in breast cancer patients raises dilemmas regarding efficacy and safety of controlled ovarian stimulation. Among these are the suggested role of malignancy and BRCA mutation in reducing ovarian response to stimulation, strategies designated to protect against hyper-estrogenic state associated with stimulation (co-treatment with tamoxifen or letrozole), and possible adjustments to accommodate oncologic-related time constraints. Conclusion Ovarian stimulation followed by IVF forms an important fertility preservation strategy for newly diagnosed young breast cancer patients, though live born rates following thawed embryo transfer in these patients are still lacking. Recent advances in controlled ovarian stimulation protocols provide practical options for some of the challenges that breast cancer patients present.

show abstract

Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer

Abstract: This retrospective analysis suggests that adjuvant chemotherapy is equally effective up to 12 weeks after definitive surgery but that RFS and OS appear to be compromised by delays of more than 12 weeks after definitive surgery.

Cited by 326 publications

References 28 publications

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation

Coordination of Radiologic and Clinical Care Reduces the Wait Time to Breast Cancer Diagnosis

IVF for fertility preservation in breast cancer patients—efficacy and safety issues

Contact Info

Product

Resources

About